Eiger Biopharmaceuticals Inc (EIGR) Stock
EIGR is no longer traded. Eiger Biopharmaceuticals was delisted from the Nasdaq in April 2024.
Prices on this page are historical; the last trade was April 11, 2024 at $2.05.
Eiger Biopharmaceuticals stock price history
EIGR final trading statistics
- Final close
- $2.05
- Final trading day
- Apr 11, 2024
- Market cap at delisting
- $3.03M
- Shares outstanding
- 1.48M
- Final 52-week range
- $0.20 – $8.27
- Avg. volume (final 3 mo.)
- 115,631
- All-time high (split-adj.)
- $12267.00 · Mar 2015
- All-time low (split-adj.)
- $1.30 · Apr 2024
- Return since IPO
- -99.9%
- Beta
- 1.84
- Book value / share
- -$1.08
- Price / book
- -1.89
Eiger Biopharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $15.77M | -$75.0M | -$10.49 |
| FY2022 | $13.48M | -$96.8M | -$2.34 |
| FY2021 | $12.14M | -$33.9M | -$2.37 |
| FY2020 | $5.74M | -$68.6M | -$2.31 |
| FY2019 | $0.00 | -$73.6M | -$3.09 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Eiger Biopharmaceuticals Inc
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
Eiger Biopharmaceuticals stock FAQ
What happened to Eiger Biopharmaceuticals stock?
Eiger Biopharmaceuticals stock was delisted from the Nasdaq. Its final close was $2.05 on April 11, 2024.
Is EIGR stock still trading?
No. EIGR was delisted from the Nasdaq in April 2024 and no longer trades on a U.S. exchange.
What was the last price of EIGR stock?
EIGR closed at $2.05 on its final trading day, April 11, 2024, for a market value of about $3.03M.
What were Eiger Biopharmaceuticals's revenue and earnings in its last full fiscal year?
Eiger Biopharmaceuticals reported revenue of $15.77M and net income of -$75.0M in fiscal 2023, its last full year as a public company.
When did Eiger Biopharmaceuticals go public?
Eiger Biopharmaceuticals Inc stock began trading on January 30, 2014.